Rolling Stone: How CBD became the unexpected star of legalized pot

Share:

Dr. Kerklaan interview quote in Rolling Stone Magazine

This is partially a matter of understanding the science behind CBD, but it’s also a matter of managing expectations. Dr. Andrew Kerklaan, a chiropractor who has a line of topical CBD creams and salves, makes an apt analogy. “A topical cream isn’t going to get rid of all your pain if you’re heading for surgery because of sciatic disc problems,” he says. “But a topical cream with CBD can still make a huge difference.”

This works, Kerklaan explains, because cannabinoids “block pain receptors, reduce inflammatory responses, and reduce muscle tension.” When a person experiences some kind of pain stimulation, Kerklaan says, “it feeds into your spine and triggers muscle tension and muscle spasm; by applying these topically at the skin level, the cannabinoids bind to some of these nerves and you’re able to turn off some of these loops and reduce the inflammatory response.” There’s a great deal of potential with CBD products but that doesn’t mean anything containing CBD is a cure for anything that ails you.

Written by Katie MacBride

Read more here.

Summarized here.

CBD, or cannabidiol, has emerged as an unexpected star in the cannabis legalization movement, distinguishing itself from THC due to its non-psychoactive properties. Unlike THC, CBD does not produce a high, making it an appealing option for consumers seeking medicinal benefits without intoxication. Its rise in popularity is largely fueled by anecdotal evidence and preliminary scientific research suggesting potential therapeutic uses for pain relief, anxiety reduction, and epilepsy treatment. As more people seek natural alternatives to pharmaceuticals, CBD has found a broad audience, from wellness enthusiasts to those suffering from chronic conditions.

The article highlights how the CBD market has exploded in recent years, thanks to shifting public perception and evolving cannabis laws. With the passage of the 2018 Farm Bill in the U.S., hemp-derived CBD became legal on a federal level, further propelling its mainstream acceptance. However, despite its rapid growth, regulation remains inconsistent, leading to concerns about product quality and efficacy. Some companies exploit the legal gray areas, making unverified claims about CBD's benefits, while scientific research continues to play catch-up.

Ultimately, the article questions whether CBD truly lives up to the hype, acknowledging both its promising potential and the need for further clinical studies. While early research and consumer testimonials suggest a wide range of health benefits, skepticism remains about its long-term efficacy and the booming industry's lack of oversight. As CBD solidifies its place in the wellness market, its future will likely depend on rigorous scientific validation and clearer regulatory frameworks to ensure consumers receive safe and effective products.